Reuters logo
BRIEF-Synlogic says ‍SYNB1020 was safe, well tolerated in subjects
November 8, 2017 / 1:30 PM / a month ago

BRIEF-Synlogic says ‍SYNB1020 was safe, well tolerated in subjects

Nov 8 (Reuters) - Synlogic Inc

* Synlogic reports positive top-line phase 1 data demonstrating safety and tolerability and proof of mechanism in healthy volunteers for synb1020, a synthetic biotictm medicine for the treatment of hyperammonemia

* Synlogic inc - ‍data support initiation of two phase 1b/2a studies in 2018​

* Synlogic - ‍synb1020 was safe, well tolerated in subjects in multiple ascending dose cohorts

* Synlogic - ‍there have been no serious adverse events, no cases of infection with bacteria in synb1020 study ​ Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below